KEI Staff's blog
Nine civil society groups write WHO Executive Board about conflict of interest on WHO R&D Financing groupSubmitted by KEI Staff on 20. January 2011 - 10:33
On January 20, 2011, 9 civil society organizations sent a letter to the WHO Executive Board registering an objection to the selection of Dr. Paul Herrling of Novartis to the WHO Consultative Expert Working Group on Research and Development: Financing and Coordination. The groups signing the letter were:
- Déclaration de Berne - Berne Declaration
- HAI Europe
- HAI Global
- Health GAP (Global Access Project)
WHO has kindly made available its conflict of interest guidelines. Apparently they are not available from the public web page. Attached are two documents:
A few of the many interesting provisions follow:
I. MEANING OF "CONFLICT OF INTEREST"
The following is an August 10, 2010 letter written by Alberto Cerda Silva, a Research Associate of Knowledge Ecology International, to Felipe Calderón Hinojosa, Presidente Constitucional de los Estados Unidos Mexicanos, regarding the position of the Mexican government in the ACTA negotiations.
On April 28, TACD will be holding a meeting from 9 am to 3 pm at the U.S. Department of Commerce, in Washington, DC, to discuss the proposed Anti-Counterfeiting Trade Agreement (ACTA).
Below are asks from the 2010 PhRMA submission to the USTR Special 301 list on the topic of drug pricing and reimbursement decisions, and described as 'Market Access Barriers.' In its assertions, PhRMA attack countries for government price negotiations, making use of reference pricing, the insufficient involvement of pharmaceutical companies in setting government pricing policies and the composition of drug formularies, among other things.
On July 28, 2006, Jeffrey Kindler replaced Hank McKinnell as CEO of Pfizer. That day the Pfizer stock price closed at $26.11. With the stock trading today at a little more than $17, it would seem that shareholders have lost a significant amount of their investment. Nonetheless, Kindler is doing well.
Billy Tauzin announced today that he will be stepping down as President and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA) at the end of June 2010.
PhRMA's 990 Tax Return Form, Schedule J-1 shows the amount Tauzin was compensated in 2008:
Base compensation: $2,055,445
Bonus & incentive compensation: $692,875
Other reportable compensation: $159,412
Deferred compensation: $1,556,960
Nontaxable benefits: $11,465
In the United States, tax exempt non-profit organizations are subject some some requirements for financial disclosure via the IRS form 990, which is available to the public. The disclosure requirements cover most U.S. based trade associations, including the Pharmaceutical Research and Manufacturers of America (PhRMA), the trade association for some 28 "member" companies.
World Health Organization (WHO) to hold consultation on report of Expert Working Group on R&D financingSubmitted by KEI Staff on 19. January 2010 - 12:14
At the end of a dramatic debate that began yesterday, the Executive Board (EB) of the World Health Organization (WHO) agreed to hold a special consultation on the report of the WHO Expert Working Group (EWG) on R&D Financing. A face-to-face meeting will be held on May 13, a few days before the 63rd WHA begins on 17 May. There will also be opportunities for web submissions on the EWG report. In addition, Dr.
February 28, 2016. KEI Contribution To The United Nations Secretary-General’s High Level Panel On Access To Medicines Trade Agreements and The Supply Of Public Goods (link here).
Report of consultations in Berlin and Geneva, forthcoming.
Congratulations on your record setting re-election as chairman of the SCCR, and for your excellent guidance this week.
With regard to the draft questionnaire, KEI suggests it be expanded to address exceptions found in Article 44 of the TRIPS, regarding alternatives to injunctions.
KEI supports the proposal by Brazil, Ecuador and Paraguay for a treaty for reading disabled persons, which is correctly inclusive in terms of disabilities covered.
Using the U.S. Freedom of Information Act (FOIA), KEI has obtained the daily schedule of Ambassador Kirk, from March 20 to May 1, 2009. KEI has separately asked the USTR to routinely as a matter of transparency post this information on the USTR web page.